ABSTRACT. Vitreous fluorophotometry was used to investigate the effect of Bendazac lysine on the blood retinal barrier in 12 insulin-dependent diabetics with mild background retinopathy. The study was a randomized, double blind, cross-over trial, drug versus Placebo. Each treatment period was of 4 months. The vitreous penetration coefficient was reduced by 21% (95% c.i. 12, 30; p = 0.001) by treatment with respect to Placebo.Key words: insulin dependent diabetes -vitreous fluorophotometry -blood-retinal barrier -Bendazac lysine -Placebo -cross-over study.Acta Ophthalmol. Scand. 1997: 75: 41 -43 itreous fluorophotometry (VFPM)
SERUM PITUITARY AUTOANTIBODIES IN CHILDREN WITH
0ept.of P e d i a t r i c s and Ophtalmology,Univ.of Parma.Italy.
INSULIN-DEPENDANT DIABETES MELLITUS (IDDM). AND CORR-
ABNORMALITIES O F BLOOD-RETINAL BARRIER (BRB) I N I D O H CHILDREN
ELATION WITH GH SECRETION AFTER TRH ADMINISTRATION.
AND ADOLESCENTSThe frequency of GH elevation observed in subjects with IDOM prompted us to look for pituitary autoantibodies. An indirect immunofluorescence technique utilizing human and guinea pig hypophysis was used to detect their presence in GH, TSII, and prolactln pituitary cells. Studies are now in progress to discriminate these specific endocrine cells autoantibodies. 26 subjects (12 boys, 14 girls, ages 7-20, mean age 12 f yr) were tested after TRH administration (7 pg/kg i.v., rnax. 200 pg). In controls, none had a significant response of plasma GI4 as defined by an increase to at least twice the baseline levels and greater than 5 ng/ml. In IODM children, a significant GH elevation was observed in 17 of 26 cases (9 girls, 8 boys) with a mean + SE level of 17.1 + 2.9 nq/ml (range 7.2 -39 nq/ml) (p<0.02 wit5 normal). Among thF responders to TRH, 14/17 had positive serum pituitary autoantibodies, while in the 9 children with no GH response to TRH, 7/9 had a negative determination. However, it is of interest to note that all patients except one had positive islet-cell antibodies in their serum In conclusion, these results are in agreement with the known paradoxical response of GH after TRH in IDDM patients, but not with the lower incidence reported in adult females. In addition, the study of pituitary autoimmunity could partly explain the changes in GH secretion observed in IDDM patients.Breakdown o f BRB i s reported as o n e o f t h e earliest retinal c h a n g e s i n adult diabetic patients (Cunha-Vaz.1975). I n t h i s s t u d y we investigated whether vitreous fluoraphotometry (VFPT) may permit t h e detection similar changes in young patients. The permeability o f BRB w a s examined by V F P H i n 3 2 young diabetic patienls (8.4-20 y r s old) and i n 1 0 non-diabetic subjects o f s a n e age. A11 p a t i e n t s had normal fundi a n d u e r e treated uith insulin injection t w i c e a day. at which time an intermediate-acting insulin is injected to cover daytime requirements. and the Deak insulin releasc a t OGTT (40-26 uU/ml) declined in a similar linear manner (r=0.97;p<0.01). Abnormal UG elevations in response to OGTT have becn noticed in all subjects a t 6 0 min. ( > 180 mg/dl)and in 3 qf them also at 180 min (> 140 mg/dl);glycosuria appeared in 2 subjects.In spite o f these abnormalities BG levels were not further contr.olled before the overt onset o f IDDM. These retr,ospective data (rarely available in the P L o f IDDM in children) confirm that the abrupt clinical onset o f diabetes may bc preceedcd b y a long period o f abnormal BG levels and insulin secretory capacity. We suggest that monitoring o f these parameters may constitute an cffcctive and non-expensive measure to identify children at risk for IDDM a...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.